NCIC Clinical Trials Group Abstracts to be presented at the ASCO 2009 Annual Meeting
Personalizing Cancer Care – May 29-June 2, Orlando, FL
BL.10 - Walter Stadler
BR.24 - Rachel A Goodwin
Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organconfined node-negative urothelial bladder cancer (UBC). (Abstract 5017)
Oral Presentation - Genitourinary Cancer (Testes, Kidney, and Bladder)
Monday: 9:30 AM - 12:15 PM, Level 2, West Hall D1
Presentation Time: 10:15 AM
Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group
study BR.24: A randomized, double-blind phase II trial of carboplatin (C) and
paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular
endothelial growth factor receptors, or placebo, in patients with advanced nonsmall cell lung cancer.
Poster Discussion - Developmental Therapeutics: Molecular Therapeutics
Friday: 2:00 PM - 6:00 PM, Level 3, W315A
Friday: 5:00 PM - 6:00 PM, Level 4, Valencia Room, W415D
Board No. 11 Abstract No. 3527
BR.10 - Mark D Vincent
Updated survival analysis of JBR.10: A randomized phase III trial of
vinorelbine/cisplatin versus observation in completely resected stage IB and II
non-small cell lung cancer (NSCLC). (Abstract 7501)
Oral Presentation - Lung Cancer - Local-Regional and Adjuvant Therapy
Monday: 3:00 PM - 6:00 PM, Level 3, Chapin Theater W320
Presentation Time: 3:15 PM
BR: 18 21 24 - Penelope A Bradbury
News Item: Dr. Goodwin has received the ASCO MERIT AWARD+ for HTN
BR.24.
CO.17 - Erin D Powell
The impact of brain metastases on overall survival (OS) in National Cancer
Institute of Canada Clinical Trials Group (NCIC CTG) clinical trials (CT) in
advanced non-small cell lung cancer (NSCLC).
General Poster Session - Lung Cancer – Metastatic
Saturday: 2:00 PM - 6:00 PM, Level 2, West Hall C
Board No. P20 Abstract No. 8075
Comorbidity and overall survival (OS) in cetuximab-treated patients with
advanced colorectal cancer (ACRC)—Results from NCIC CTG CO.17: A phase
III trial of cetuximab versus best supportive care (BSC).
General Poster Session - Gastrointestinal (Colorectal) Cancer
Sunday: 8:00 AM - 12:00 PM, Level 2, West Hall C
Board No. G14 Abstract No. 4074
News Item: NOYCIA Award* to be presented to Penny Bradbury at a Sunday
evening dinner at ASCO.
CO.17 - Derek J Jonker
BR.21 - Glenwood D Goss
TGF-α and amphiregulin levels in non-small cell lung cancer (NSCLC) patients
(pts) treated with erlotinib/placebo in the National Cancer Institute of Canada
Clinical Trials Group (NCIC CTG) BR.21.
Poster Discussion - Tumor Biology and Human Genetics
Sunday: 2:00 PM - 6:00 PM, Level 2, W240A
Sunday: 5:00 PM - 6:00 PM, Level 3, W304A
Board No. 12 Abstract No. 11023
High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as
predictors of cetuximab benefit in the treatment of advanced colorectal cancer
(ACRC): Results from NCIC CTG CO.17—A phase III trial of cetuximab versus
best supportive care (BSC).
Poster Discussion - Gastrointestinal (Colorectal) Cancer
Monday: 8:00 AM - 12:00 PM, Level 2, W240A
Monday: 11:00 AM - 12:00 PM, Level 2, West Hall E1
Board No. 7 Abstract 4016
* Novartis Oncology Young Canadian Investigator Award (NOYCIA)
NOYCIA is a national competition for residents, fellows, post-doctorate students or PhD candidates. The program is dedicated to advancing the field of oncology through the promotion of research. This year 31
abstracts were eligible, submitted and considered by the scientific panel. Following extensive and objective deliberation, ten winners from across Canada were selected.
+ ASCO Cancer Foundation Merit Award
A select number of ASCO Cancer Foundation Merit Awards are given annually to recognize outstanding abstracts submitted for consideration for presentation at an ASCO scientific meeting. The awards are
given to oncology fellows who are first authors on selected abstracts. They are designed to promote clinical research by young scientists and to provide fellows with an opportunity to present their research and
interact with other clinical cancer investigators at ASCO scientific meetings.
NCIC Clinical Trials Group Abstracts to be presented at the ASCO 2009 Annual Meeting
Personalizing Cancer Care – May 29-June 2, Orlando, FL
IND: 126 148 160 EN5 - Helen Mackay
MA.14 - Ettie Piura
Microsatellite instability and loss of PTEN expression in early versus late-stage
endometrial cancer: Results from studies of the National Cancer Institute of
Canada Clinical Trials Group (NCIC-CTG).
Poster Discussion - Gynecologic Cancer
Monday: 2:00 PM - 6:00 PM, Level 3, W340A
Monday: 5:00 PM - 6:00 PM, Level 2, West Hall F3
Board No. 24 Abstract No. 5534
Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer
(BC) patients: NCIC-CTG MA14 trial.
Poster Discussion - Breast Cancer - Local-Regional and Adjuvant Therapy
Sunday: 8:00 AM - 12:00 PM, Level 2, W240A
Sunday: 11:00 AM - 12:00 PM, Level 2, West Hall D1
Board No. 19 Abstract No. 534
IND.162 - Warren P Mason
A phase I study of temozolomide (TMZ) and RAD001 in patients (pts) with
glioblastoma multiforme (GBM).
General Poster Session - Central Nervous System Tumors
Sunday: 8:00 AM - 12:00 PM, Level 2, West Hall C
Board No. A12 Abstract No. 2036
IND.165 - Kim N Chi
Mature results of a randomized phase II study of OGX-011 in combination with
docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic
castration-resistant prostate cancer. (Abstract 5012)
Oral Presentation - Genitourinary Cancer (Prostate)
Saturday: 3:00 PM - 5:30 PM - Level 3, Chapin Theater W320
Presentation time: 4:30 PM
IND.179 - Amit M Oza
Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients
(pts) with advanced solid tumors: NCIC CTG IND 179.
General Poster Session - Developmental Therapeutics
Saturday: 8:00 AM - 12:00 PM, Level 2, West Hall C
Board No. H14 Abstract No. 3558
MA.5 – Maggie Chon U Cheang
Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing
adjuvant CMF to CEF.
Poster Discussion -Breast Cancer - Local-Regional and Adjuvant Therapy
Sunday: 8:00 AM - 12:00 PM, Level 2, W240A
Sunday: 11:00 AM - 12:00 PM, Level 2, West Hall D1
Board No. 4 Abstract No. 519
MA.14 - Suhail M Ali
Effect of adjuvant chemotherapy on bone resorption marker beta C-telopeptide
(B-CTX) in postmenopausal women.
General Poster Session - Breast Cancer - Local-Regional and Adjuvant Therapy
Monday: 1:00 PM - 5:00 PM, Level 2, West Hall C
Board No. E7 Abstract No. 594
OV.17 - Eric Pujade-Lauraine
A randomized phase III study of carboplatin (C) & pegylated liposomal
doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P) in relapsed
platinum-sensitive ovarian cancer (OC): CALYPSO study of Gynecologic Cancer
Intergroup (GCIG). (Abstract LBA5509)
Oral Presentation - Gynecologic Cancer
Sunday: 9:00 AM - 12:00 PM, Level 3, Chapin Theater W320
Presentation Time: 11:15 AM
General - Christopher M. Booth
Evaluating Cancer Therapies in RCTs and Beyond: What Leads to Real Benefit
in the Real World?
Education Session: New Endpoints for New Treatments: A Time for Change in
Assessing Treatment Benefit
Sunday: 11:30 AM – 12:45 PM, Level 4, Valencia Room, W415A
General - Pavlo Ohorodnyk
Clinical benefit in oncology trials: Is this a patient-centered or tumor-centered
endpoint?
General Poster Session - Health Services Research
Saturday: 2:00 PM - 6:00 PM, Level 2, West Hall C
Board No. C11 Abstract No. 6564
Publication only at www.asco.org and www.jco.org
PA: 1 3: Dhani NC, Tu D, Parulekar W, Seymour L. A retrospective analysis of tumour size as a continuous rather than discrete variable in advanced pancreatic cancer. (Abstract No. e15565)
Mittmann N, Leighl N, Rocchi A, Krahn M, Peacock S, Taylor S, Au H-J, Oh P, Jacobs P, Reynard P, Husereau D, Isogai P, Longo C, Marshall D, Coyle D, Meyer R, Kee P, Tryan D. Economic guidelines for
oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document. (Abstract No e17572)